TAS-102 for the treatment of metastatic colorectal cancer-Reference-Cited by-同舟云学术

TAS-102 for the treatment of metastatic colorectal cancer

Published:2015-10-28 Issue:11 Volume:15 Page:1283-1292
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Salvatore Lisa,Rossini Daniele,Moretto Roberto,Cremolini Chiara,Schirripa Marta,Antoniotti Carlotta,Marmorino Federica,Loupakis Fotios,Falcone Alfredo,Masi Gianluca

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737140.2015.1105746

Reference37 articles.

1. Dietary patterns and colorectal cancer

2. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

3. Global cancer statistics, 2012

4. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

5. Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trifluridine and Tipiracil Hydrochloride Combination-Induced Interstitial Pneumonia: A Case Report;International Medical Case Reports Journal;2024-02

2. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer;Journal of Clinical Medicine;2023-12-21

3. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study;Clinical Colorectal Cancer;2023-03

4. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis;Clinical Colorectal Cancer;2020-06

5. Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer;Bioengineering & Translational Medicine;2020-05-28